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Conclusions: k: enterocolitica constituted the majority of causative 
agents of acute appendicitis 11/25 (44%). The recommended drugs 
for k: enterocolitica infection were chloramphenicol, gentamicin, tetra- 
cycline and trimethoprimsulfamethoxazole. 
The microflora of the intestinal tract as a 
reservoir for microbial translocation-is it 
similar in young children of Sweden and 
Estonia? 
M. Mikelsaar, E. Sepp, K. Julge, M. Vasar, K. Duchh,  B. 
Bjorkst6n. Department of Microbiology, University of Tartu, Estonia; 
University of linkiiping, Sweden 
Objectives: The imbalance of the normal microflora serves as direct 
precondition for translocation of opportunistic pathogens to lymph 
nodes and blood from mucosa. Experimentally, the close correlation 
between the high numbers of opportunistic microbes of gut and their 
translocation has been revealed. The aim of our study was to find out 
whether there are any differences in intestinal microflora composi- 
tion of Swedish and Estonian 2-year-old children. 
Methods: Altogether, 30 Estonian and 36 Swedish 2-year-old 
children born in 1995 in Tartu (Estonia) and Linkoping (Sweden) 
were recruited in the study. In their fecal samples, 13 groups of aero- 
bic, micro-aerophilic and anaerobic bacteria were quantified (log 
CFU/g feces) by serial dilutions on 10 different media. Non-para- 
metric Mann-Whitney test was applied for statistical evaluation of 
data. 
Results: Concerning opportunistic pathogens, the Swedish 2- 
year-old children were more often and in greater numbers colonized 
with Staphylococcus aureus as compared to Estonian children 
(p<0.001). At the same time, the latter showed more frequent preva- 
lence and higher counts of Candida spp. than Swedes (p<O.O01). 
Some differences were also revealed in the intestinal indigenous 
microbiota: in Sweden, there was more intensive colonization with 
both bifidobacteria and bacteroides @<0.01), while in Estonians 
colonization by lactic acid-producing streptococci (p<O.Ol) could be 
revealed. 
Conclusions: The intestinal microflora of 2-year-old Swedish 
and Estonian children were not similar and it should he kept in mind 
that there is a possibility of clinical infections by pathogenic staphy- 
lococci in Swedes and by Candida in Estonians. 
Respiratory tract infections 
(p7021 The most frequent bacterial agents in 
respiratory infections 
L. Trajanovic, M. Maneva, T. Ilieversuska, 0. Stefanoversuska 
Institutefor Respiratory Diseases in Children, Skopje, Macedonia 
Follow-up of the isolates of materials from the respiratory tract over 
a period of 6 months is necessary in every hospital for lung diseases. 
Our aim was to evaluate a group of 480 children from the depart- 
ment for intensive care and the department for chronic lung diseases 
who were subjected to drainage secretions and bronchial aspirate. 
We obtained these results: 
Baclerial agents IMensiVeCare Chronicdiseases 
Streptococcus pneum, 16 (06.15%) 19 (08.6%) 
Haemophifus spp. 
Mormela cat. 
Slaph. Aureus 
Staph. coagdneg. 
Escherichia coli 
Klebsiela spp. 
Pseudomanas aerugenosa 
Proleus mirab. 
Enterobacter spp. 
Achetobacter spp. 
Streptocwcus beta ham. 
Candida spp. 
8 (0.76%) 
2 (0.76%) 
25 (09.6%) 
9 (03.45%) 
5 (01.92Ye) 
6 (02.3%) 
9 (03.46%) 
1(0.38%) 
2 (0.76%) 
I 
19 (7.3%) 
18 (06.9%) 
16 (07.2%) 
7 (03.18%) 
3 (01.36%) 
I 
7 (03.1%) 
1(0.45%) 
9 (04.09%) 
3 (01.36%) 
/ 
I 
1 (0.45%) 
8 (03.6%) 
On the basis of these results we can conclude that in the drainage 
secretions of all children Gram negative flora was dominant. Because 
of this, it is necessary to follow up the isolates for adequate and timely 
treatment with antibiotics, and to be aware ofthe epidemiologic situ- 
ation in the department, patients' social status and excessive use of 
antibiotics. 
Characteristics of N. meningitidis, H. influenzae 
and S. pneumoniae strains isolated from upper 
respiratory tracts of healthy people 
W. Grzybowska', G. Duin?, T. Zareba', S .  Tyski'. 'Antibiotics and 
Microbiology Department, Drug Institute, 'Warsaw Sanitary and 
Epidemiologic Station, Warsaq  Poland 
N meningitidis, H. injuenzoe and S. pneumoniae strains are among the 
main bacterial pathogens of the respiratory and central nervous 
systems. These infections begin with nasopharynx bacterial colo- 
nization. The carrier status of particular pathogens is correlated with 
human age. Nasopharyngeal swabs were taken from over 100 
children 1-5 years old in order to establish H.  inzuenzae carrier status 
and from 6-year-old and 14-year-old children to look into S. 
pneumoniae and N. meningitidis colonization respectively. Almost 150 
military recruits were assayed to detect the above-mentioned micro- 
organisms. A longitudinal study (2 months) of A! meningitidis carrier 
status was also performed. All obtained isolates were phenotypically 
characterized, and MICs of selected antimicrobial agents were esti- 
mated. 
A non-meningococcal strain was isolated from children. Over 50 
phenotypically differerent N. meningitidis isolates were obtained from 
recruits' swabs. The dominant meningococcal phenotypes were 
NG21P1.7 and B21P1.7. All isolates were susceptible to penicillin, 
cefotaxime, ciprofloxacin, chloramphenicol, tetracycline, and sulfon- 
amides. H. injuenzae strains were isolated &om 28% of healthy young 
children and from 11% of recruits. All obtained strains were non- 
groupable except two serogroup b strains obtained from children. 
Biotypes 1, and then V and 11, were the most common. 6% and 20% 
of isolates were penicillin and sulfamethoxazole resistant, respectiveiy. 
Pneumococci were recovered from 9% of children and 19% of 
recruits. All isolates were sensitive to penicillin. 
[p7041 Chlamydia pneumoniee (Cp) detection in 
oropharynx by direct immunofluorescence 
(DIF) test 
I. Choroszy-Krd, J. Ruczkowska. Department ojMicrobiolop~, 
Wroclaw University of Medicine, Wroclaw, Poland 
Objectives: Cp is a pathogen of lower and upper respiratory tract 
infection (RTI) but has also been found in retropharyngeal swabs of 
healthy individuals. The aim of this study was to evaluate the 
frequency of Cp colonization in oropharynx. 
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Methods: Between April 1995 and July 1998 we examined 4128 
patients with URTI and LRTI; 1229 adults (764 women, 465 men) 
aged 18-86 years and 2899 children (1506 girls and 1393 boys) aged 
2.5-17 years. Oropharyngeal swabs were collected from 4128 patients 
and 50 healthy laboratory staff (control group). Specimens werEtested 
for Cp by DIF technique (Chlamydia pneumorziae FITC Research, 
Dako, Denmark). 
Results: Positive DIF results were found in 1016 (24.6%) out of 
4128 examined patients; 319/1229 (25.9%) in adults and 697/2899 
(24.0%) in children, without any differences related to sex or age. 
921 365 (25.2%) patients re-examined after treatment were DIF'. In 
the control group there were 1150 (2.0%) DIF+. 
Conclusions: Sore throat and dry cough are symptoms 
conimonly associated with Cp infection. Eradication of Cp after 
treatment was not complete, as one fourth of treated patients still 
harbored Cp in the oropharynx. The incidence of C P  in healthy 
laboratory staff was very low (2.0%). 
m1 Evaluation of susceptibility of Pseudomonas 
aeruginosa strains isolated from cystic fibrosis 
patients 
A. Herrero, B. Buendia, T. Alarcbn, M. Lbpez-Brh. Department .f 
Microbiologfi Hospital La Pvincesa, Madrid, Spain 
Objectives: To study the susceptibility of all Pseudomonas aenrginosa 
and of the different colonial morphotypes, isolated from sputum from 
cystic fibrosis patients. 
Methods: The susceptibility of 78 isolates of Pseudomonas aerugi- 
~ O S Q  isolated from sputum of 10 adult patients with cystic fibrosis over 
1.5 years were studied. The susceptibility tests to aztreonam (AZT), 
cystic fibrosis, by determination of susceptibility to different beta- 
lactam antibiotics. 
Methods: The susceptibility of 78 strains of Prcudornotias acrid@- 
nosa isolated from 10 adult patients with cystic fibrosis over 1.5 years 
were studied. The susceptibility tests to aztreonani, ceftazidinie, 
piperacillin and imipenem were carried out by a comniercial micro- 
dilution technique (Microscan, DADE), and to cefepinie and piper- 
acillin-tazobactam by the disk difusion technique. The imipenem 
resistance way confirmed by agar dilution technique. Standard 
NCCLS susceptibility and resistance breakpoints were applied. A 
totally derepressed strain was suspected when cefepime was affected. 
Results: Seven $trains of Pselrdonionar aenr@uosa (9%) were resis- 
tant to aztreonam, ceftazidime and cefepime, in addition to 
piperacillin-tazobactam. Six strains were isolated from the same 
patient (with different morphotypes and susceptibility co other non- 
beta-lactain antibiotics) and they developed resistance in the iaq 4 
months, after repeated hospitalization of the patient and treatment 
with beta-lactams. The imipenem remained active. 
Conclusions: (1) The resistance to aztreonam, ceftazidime and 
cefepime could be indicative of the existence of total derepressed- 
chromosomal fl-lactainase in Pseudomoans aeruginusa. (2) A judicious 
use of the antibiotics is necessary because the selection of totally or 
partially derepressed mutants of Pseudomonas aemginosa could occur 
during antipseudomonal therapy with labile weak inducers of B- 
lactaniase such as piperacillin and extended-spectrum cephalosporins. 
Variability and persistence of 
Stenofrophomonas maltophilia isolates in 
cystic fibrosis settings 
ceftazidime (CTZ), piperacillin (PI), ciprofloxacin (CIP), amikacin 
(AK), tobramycin (TOB), gentamicin (GEN) and imipenem (IMP) 
were carried out by a commercial microdilution technique (Micro- 
Scan, DADE), and piperacillin-tazobactani (PITA) using the disk 
difusion technique. The imipenem resistance was confirmed by agar 
S. Valdezate', A. Vindel' , F. Baquero', E. Goniez-Sanz', 1'. 
Trincado', L. Azanedo', R. Canton'. 'Servicio de Miirobiolo@a, 
Hospital Ramon y Cajal, 'Centro National de Microbiolo~qin, Znrtituto 
Carlos Ill, Majadahonda, Madrid, Spain 
dilution technique. Standard NCCLS breakpoints were applied. 
Results: The colonial morphotypes were as follows: mucoid 
(26%), rough (34%), dwarf (21.9%), enterohacterial (9.6%), gelati- 
nous (12.3%) and metallic (2%). They presented different suscepti- 
bility patterns. 
Conclusions: The multiple varieties of Pseudomonas aenrginosa 
often found in a single culture may not have the same susceptibility 
patterns. We confirm the data from other authors that the mucoid 
phenotype is more sensitive than other morphotypes. Due to high 
rates of resistance, the susceptibility must be monitored to choose the 
appropriate treatment. 
[p7061 Study of total derepressed chromosomal R- 
lactamase in Pseudomonas aeruginosa in 
patients with cystic fibrosis 
A. Herrero, B. Buendia, T. Alarcon, M. Lopez- Brea. Dvpartment .f 
Microbiology, Hospilal La P r i n i m ,  Madrid, Spain 
Objetives: Preliminary study of the strains of Pseudomonas aemginosa 
with total derepressed-chromosomal B-lactamase from patients with 
Objectives: To assess the epideniiology of S. nialtophilia (SM) colo- 
nization/infectioii in cystic fibrosis patients (CF) and age-incidence 
rates of acquisition. 
Methods: Seventy-four SM isolates were recovered from 1991 to 
1998 in respiratory sources from 22 CF patients. Two different groups 
of 11 patients were considered: (i) single episode of SM (SE); and (11) 
repetitive SM episodes (RE). Eleven isolates froiii thc SE and 63 
isolates from the R E  group were characterized by pulsed-field gel 
electrophoresis (PFGE) to determine whether or not CF patients 
were colonized/infected with the same strain and whether there was 
cross-infection. 
Results: At least one SM episode took place in 27'% (22/81) of 
CF patients during the 7-year period, with a yearly incidence rang- 
ing from 0% to 7.4%. After PGFE, the real incidence increased from 
2.5% to 12.3% as a result of the acquisition of new strains displaying 
different PFGE profiles in R E  patients. The main age range of SM 
acquisition in SE patients was 6-10 years, while for the RE group 
the first SM acquisition occurred at 16-20 years. In both groups, SM 
isolates showed a high degree of PFGE heterogeneity. Each KE 
patient harbored from 2 to 5 strains with different PFGE profiles. 
Cross-infection was suggested in 2 and 3 patients by two different 
mains. 
Conclusions: The PFGE was a useful tool to establish the real 
SM incidence in CF patients. 
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Ip7081 Haemophilus influenzae infection in pulmonary 
patients 
M. Faustova, L. Vishniakova. Deparfment ofMicrobiolq8 The State 
Research Centerfor P u l m o n o l o ~ ~  St Petersburg, Russia 
Objectives: At present it is known that the infectious process in the 
bronchial tree is caused by non-typeable H. injuenzae strains. 
Methods: Isolation and identification of H. injuenzae from 
patients with pulmonary diseases was assessed by standard methods. 
Neuraminidase activity was assessed by a modified resorcin method 
(substrate: lyophilized ovomucin), and hyaluronidase and protease 
activity by conventional methods. We studied an effect of H. injuen- 
r a e  on rheologic properties of sputum (Rheotester, Russia, RAS). 
The synthesis of histamine from histidine (in vitro) was determined 
by a fluoronietric method. The production of anti-Haemophilus anti- 
bodies was determined by an indirect immunofluorescencEtest. 
Results: We demonstrated an absence of hyaluronidase and low 
contents of neuraminidase strains of H. in$ueuae isolated from 
pulmonary patients. In vitro results of the effect of H. it$uenzae on 
rheologic properties of sputum were of three types: insignificant 
changes in viscosity, marked decrease in viscosity, formation of clus- 
ters. The fluidification was characteristic for cystic fibrosis, increas- 
ing viscosity for bronchial asthma. The analysis of histamine synthesis 
in 100 H. injirenzae strains isolated from patients with pulmonary 
diseases demonstrated that strains synthesized it to a great extent: 
from 0 to 38 mg/mL (mean value 9.4 mg/mL). High values of in 
vitro histamine synthesis were associated with marked bronchial 
obstruction in asthma patients, but in obliterating bronchiolitis and 
cystic fibrosis this correlation was not found. The level of H. injuen- 
zap is always higher than the level of its confirmed etiologic role. In 
such cases, generally accepted criteria of etiologic importance, based 
on agent isolation in diagnostic concentrations from bronchial secre- 
tions, as well as evolution of antibody titers, are unable to demon- 
strate the role of H. injirenzae in etiology diseases. 
Conclusions: When H. iqfiuenzae is found in the bronchial tree, 
its etiologic role is not always demonstrated, but its participation in 
pathogenic mechanisms of bronchial injuries is not doubted. 
/p709] Sensitivity of Streptococcus pneumoniae and 
Haemophilus influenzae strains isolated from 
respiratory patients 
M. Faustova, Y. Reztsova, T. Sologub, I. Moshkevitch, L. 
Vishniakova. Department of Microbiolon, State Research Centerfor 
Pulmonolo~): Sf Petersbutg, Russia 
Objectives: Between 1991 and 1998, we determined the sensitivity 
to antibacterial drugs of 1377 strains of S. pneumoniae and 756 strains 
of H. injluenzae isolated in patients with respiratory diseases. 
Methods: The isolation and identification of S. pneumoniae and 
H. injuenzae were carried out by standard methods. We used disks 
with antibacterial drugs of the penicillin class, cephalosporins, tetra- 
cyclines, niacrolides, quinolones, and other antibiotics. 
Results: Within the investigation period, the frequency of sensi- 
tive strains of S. pneumoniae was 8@97% with the exception of tetra- 
cycline (23-36%) and gentamicin (10-12%). We established a high 
resistance of strains of H. injuenzae to B-lactam antibiotics of the 
penicillin class and some cephalosporins. A majority of non-typeable 
H. inyuenzae strains circulating in St Petersburg are sensitive to tetra- 
cycline (60-75%), chlorampbenicol (80-93%), rifampicin (76-82%), 
and cefaclor (87%) (1991-98). A trend to increasing frequency of 
pneuinococci resistant to penicillin was established (8.3-21.5%). In 
addition to resistance to penicillin, 65-77% of pneuniococcal strains 
were multiresistant to 6-8 antibiotics. From 8% to 25% of examined 
H. injuenzae were multiresistant to most antibiotics. In pulmonary 
diseases, there is a simultaneous course of several infectious processes 
provoked by agents having different non-matching sensitivity to 
antibiotics. In this way, in cases of simultaneous isolation of Pneumo- 
coccus and H .  injuenrae, the former is highly sensitive to penicillins 
and cephalosporins, to which H. injuenzae is resistant. The antibi- 
otics of choice for both of them are chloramphenicol, rifampicin and 
cefaclor. 
Conclusions: The data obtained provide evidence of the neces- 
sity of microbiological analysis of pathologic material for the 
adequate prescription of antibacterial therapy. 
[ P 7 1 q  Effects of an empirical time-changed antibiotic 
therapy on exacerbations of COPD 
R. Bilancia, L. Mastrandrea, G. Caputo, R. Chianese, P. Bisceglie. 
Department $Respiratory Diseases, University of Bari, Italy 
Objectives: To evaluate the effect of an empirical time-changed 
antibiotic therapy on the hospitalization frequency and on the bacte- 
rial antibiotic resistance in patients (pts) with COPD exacerbations. 
Methods: We studied 31 pts (17M, 14F; mean age 68.1t3.4 
years) over 24 months. All pts had COPD and 26 (83.8%) were 
submitted to mechanical ventilation (VAM). During the first 12 
months (before period) the pts were hospitalized when they showed 
an exacerbation. In the following 12-month period (after period) we 
treated at home every exacerbation. In case of treatment failure (no 
clinical improvement after 10 days of therapy) we hospitalized the pts. 
An empirical scheduled change of antibiotic (a third-generation 
cephalosporin; a quinolone; a carbapenem), based on previous 
microbiological diagnosis and antibiotic resistance evaluation, was 
used for the treatment at home. 
Results: We observed the following results: 
I hospitalization I mean for each pt. 1 No of antibiotic 
Conclusions: Our data show that an empirical scheduled change 
of antibiotic therapy can reduce the hospitalization frequency for 
COPD exacerbation without causing a large increase in antibiotic 
resistance. 
m1 Once-daily trovafloxacin versus twice-daily 
ciprofloxacin in the treatment of acute 
exacerbations of chronic bronchitis (AECB) 
C. Stahl-Bayliss, the Trovafloxacin Study Group. Pjzer  Znc., New 
York, Nk: USA 
Objectives: To evaluate the clinical and bacteriologic efficacy and 
toleration of once-daily trovafloxacin versus twice-daily ciprofloxacin 
in the treatment of AECB. 
Patients and methods: In this multicenter, randomized, double- 
blind, double-dummy study, Anthonisen Type 1 AECB patients 
received either trovafloxacin 200 mg 0.d. for 5 days or ciprofloxacin 
500 mg b i d .  for 7 days. Clinical and bacteriologic responses were 
monitored at the end of therapy (EOT, day 7), follow-up (FU, days 
24-30), and end of study (EOS, days 85-95). 
Results: At EOT, clinical success (cure or improvement) was 
recorded in 95% (n=169) and 93% (n=169) of clinically evaluable 
patients receiving trovafloxacin and ciprofloxacin, respectively. At FU, 
respective rates were 84% (n=159) and 61% (n=163). By EOS, the 
incidence of clinical success rates was significantly higher @=0.042) 
in trovafloxacin patients: 71% (n= 148) versus 61% (n=150). A signif- 
A b s t r a c t s  2 7 5  
H. influenme 
5. oneurnaniae 
icantly lower proportion of trovafloxacin patients relapsed by EOS 
(25% versus 35%; p=0.048). At EOT, respective eradication rates 
with trovafloxacin and ciprofloxacin were 97% and 97% for H .  
irifkrenzae, 72% and 60% for S. pneuntoniae, and 80% and 100% for 
M. catarr/iali.c. By EOS, rates were 85% and 79% for H. iy'henzae, 
72% and 55% for S. pneuniotiine and 87% and 56% for M .  catarrhah. 
Incidences of treatment-related adverse events were similar in 
trovafloxacin and ciprofloxacin patients; the majority were of mild or 
moderate intensity. Treatment was discontinued in 11 trovafloxacin 
and 8 ciprofloxacin patients due to gastrointestinal intolerance (7 
versus 4) or central nervous system symptoms (4 versus 4) 
Conclusions: Trovafloxacin provides a clinically and bacteriolog- 
ically effective therapy of A E C ~ ~ S ,  and significantly reduces the inci- 
dence of relapse compared with ciprofloxacin. Cost savings may be 
achieved with trovafloxacin's lower relapse rate. 
35/40 188%) 38/43 (88W 27/48 155%) 
12/14 186%) 9/9(1CVd 11/18161%~ 
(p7121 A multicenter study of short-course 
grepafloxacin therapy versus clarithromycin in 
the treatment of patients with acute bacterial 
exacerbation of chronic bronchitis (ABECB) 
M: catorrtmtis 
H. parainfluenme 
5. aureus 
C. Langan', C.  Mars ,  H. Staley', the Raxar ABECB Study 
Group. 'Baillieston Health Center, Glas<qow, 'Departmenf  ofb2fectious 
Dismes, Glnxo Wllcumc Research, Middlesex, UK 
Objectives: To compare the efficacy of grepafloxacin 400 mg 0.d. 
for 5 (GFX-5) or 10 (GFX-10) days with clarithromycin (CLA) 250 
nig b.i.d. for 10 days in ABECB. 
Methods: In an international, randomized, double-blind study 
with 78 centers from nine countries (Belgium, Canada, the Czech 
Republic, France, Germany, Poland, Portugal, Spain and the UK), 
805 patients were recruited. Of these, 802 patients were randomized: 
273 received GFX-5, 268 GFX-I0 and 261 CLA. Patients were 
assessed clinically and bacteriologically pretreatment, on days 3-5 
during treatment, 1-3 days post-treatment and 21-28 days of follow- 
UP. 
Results: Clinical success was achieved in 91% (142/156) of evalu- 
able patients in the GFX-5 group, 95%) (149/157) in the GFX-20 
group and 86% (137/160) in the CLA group at post-treatment. 
Clinical success was maintained at follow-up in 72%1, 81% and 73% 
of GFX-5, GFX-IO and CLA patients, respectively. A total of 513 
pretreatment pathogens were isolated in 400 (49 patients, the primary 
pathogens being H .  influenme (36% of isolates), H. parainfuenzae 
(27%), M.  tarnkarralis (12%) and S. pneumoniae (1 1%). Bacteriologic 
success at post-treatment was achieved in 8596, 91% and 58% of 
evaluable patients treated with GFX-5, GFX-10 or CLA, respec- 
tively. All treatment groups were well tolerated, the most commonly 
reported drug-related adverse events (AE) in the GFX-5, GFX-1 0 or 
CLA groups being nausea (2%, 4%, 2%). vomiting (<1%1, 3%, 2%) 
and abnormal unusual taste (376, 596, < 1%). Discontinuation from 
treatment due to AE, iiiostly nausea or vomiting, was 2% for both 
GFX groups and 4% for CLA. 
Conclusions: Both a 5-day and a 10-day regimen of GFX 400 
nig once daily were as clinically and bacteriologicaUy effective as CLA 
250 mg twice daily for 10 days in ABECB. The potential lower cost 
and better compliance of 5-day GFX make it an attractive therapeu- 
tic option in the treatment of ABECB. 
lo l l2  (83%) 14115 (93%) 13/14 [934bI 
29/31 194%) 26/29 (90%) 19/37 I51%1 
2/2 11m1 2/2 ( 1  00%) 5/7 171%) 
m1 Comparison of bacteriologic efficacy of short- 
course grepafloxacin therapy versus 
clarithromycin in the treatment of acute 
bacterial exacerbation of chronic bronchitis 
(ABECB) 
C. Langan', C. Mars ,  H. Staley', the Raxar AUCEB Study 
Group. 'Baillieston Health Center, Glaspw, 'Department CJJ Ir~rfrrtiorrs 
Diseases, GIaxo Wellcome Research, Middlcsex, C!K 
Objectives: To compare the bacteriologic efficacy of grepafloxacin 
400 mg o.d. for 5 (GFX-5) or 10 (GFX-10) days with clarithroiiiycin 
(CLA) 250 mg b.i.d. for 10 days in ABECB. 
Methods: In an international, randomized, double-blind study 
with 78 centen from nine countries, 805 patients were recruited. Of 
these, 802 patients were randomized: 273 received GFX-5, 268 
GFX-10 and 261 CLA. Patients were assessed clinically and bacteri- 
ologically pretreatment, on days 3-5 during treatment, 1-3 days post- 
treatment. and 21-28 days of follow-up. 
Results: Pretreatment pathogens were confirmed in 400 (4Y'%,) 
patient$: H .  inJuenzae (36% of isolates), H .  parait$puemac (27%), iL1. 
cataharrdis (12%), S. pneumoniae (1 1%) and S. anreus (3%). Overall 
bacteriologic success at post-treatment was achieved in 85%1,91%i and 
58% of evaluable patients treated with GFX-5, GFX-10 or <:LA, 
respectively. By-pathogen bacteriologic success rate a t  post-treatnient 
was: 
1 P7 14 1 Geographic comparison of short-course 
grepafloxacin therapy versus clarithromycin in 
the treatment of patients with acute bacterial 
exacerbation of chronic bronchitis (ABECB) 
E Vogrl', C. Marr', H. Staley', the Raxar AUECU Study Group. 
'Medizinisclie Klinik 111, Hqfieim, Gerniany; 'Departnicwt of IilfCctiorrs 
Diseasrs, Glaxo Wellconic Research, Middlesex, U K  
Objectives: To compare the efficacy of grepafloxacin 400 nig o.d. 
for 5 (GFX-5) or 10 (GFX-10) days with clarithromycin (CLA) 2.50 
nig b.i.d. for 10 days in ABECB patients recruited in eastern Europe, 
France and Germany 
Methods: In an international, randomized, double-blind study 
with 78 centers from nine countries, 805 patients were recruited: 162 
from eastern Europe (the Czech Republic and Poland), 109 from 
France, 94 from Germany, and the r a t  from 13elgium, Canada, 
Portugal, Spain and the UK. Patients were assessed clnilcally and 
bacteriologically pretreatment, on days 3-5 during treatment, days 
1-3 post-treatment. and 21-28 days of follow-up. 
Results: In Germany, both CFX-5 and GFX-I0 groups showed 
a higher clinical success rate in the evaluable patients than thr CLA 
group a t  follow-up. In eastern Europe and France, the clinical success 
rates in all groups were comparable: 
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Eastern Europe 
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A double-blind comparison of oral levofloxacin 
500 mg once daily for 5 days with oral 
levofloxacin 500 mg once daily for 7 days in 
patients with acute exacerbation of chronic 
bronchitis 
CJ. Burley', R.G. Masterton'. 'HoeckJt Marion Rotcssel, Denhnm, 
' We5tern General Hospital, Edinburgh, UK 
Objectives: To establish whether the clinical efficacy of 5 days of 
treatment with oral levofloxacin 500 nig once daily is equivalent to 
that of 7 days of treatment with the same dose in patients with acute 
exacerbation of chronic bronchitis (AECB). 
Methods: This study was performed at 48 centers, in 10 coun- 
tries from Europe and Latin America. 500 patients with increased 
sputum purulence plus 2 other symptoms from increased cough, 
dyspnea or sputum volume were entered into the study to obtain 300 
evaluable patients. Patients were assessed at: study entry, end of treat- 
ment, 7-10 days post-treatment and follow-up. Both clinical and 
bacteriologic eficacy were examined and all adverse events were 
recorded. 
Results: A total of 532 patients were randomized into the study 
between 23 June 1997 and 3 April 1998. Clinical success rates in the 
per-protocol (PP) analysis at the post-treatment visit were 83% in the 
5-day group and 85% in the 7-day group. The difference in success 
rates was 2% and the 95% C1 ofthe differences was (-9.1% to 5.1%) 
Analysis of the clinical success rate in the intention-to treat (ITT) 
population corroborated this equivalence. The bacteriologic response 
at the post-treatment visit showed eradication rates of 82% and 83% 
the 5-day and 7-day groups respectively, indicating equivalence in the 
bacteriologic response. The most frequently reported adverse events 
in the 5-day and 7-day groups were diarrhea (6%, 3%), headache (4%, 
4%) and nausea (3%, 4%). There were no reports of photosensitivity, 
convulsions or tendinitis. 
Conclusions: This study demonstrates that for patients with 
AECB a 5-day course of oral levofloxacin, 500 mg once daily, is as 
effective as the present standard 7-day course at the same dose. 
Ip7161 Spiramycin versus roxithromycin in 
community-acquired pneumonia (CAP) and 
acute exacerbation of chronic bronchitis 
IAECB) 
V. Nonikov', A. Burova', S .  Yakovlev2, S. Ovtcharenkoz, T. 
Fedorova', A. Sinopalnikov3, 0. Peshkova4, 0. Korovina', V. 
Simanenkov', M. likovitch". 'Department .f Pulmonolou, Central 
Clinical Hospital, 'Moscow Medical Academy, jRussian Academy o f  
Postpduate Medical Education, 4Municipal Ambulance, Moscow, 
sAcademy .f Postgraduate Medical Education, 6State Research Center o f  
Pulmonology, St Detersburf, Russia 
Objectives: Comparison of two macrolides b.i.d. in the treatment 
of CAP and AECB. 
Methods: A phase IV open-label evaluator-blind randomized 
parallel-group multicenter study (January to October 1998) compar- 
ing the eficacy and safety of oral spiramycin (3 MIU b.i.d.) with 
those of oral roxithromycin (150 mg b.i.d.) in CAP (77 patients) and 
AECB (125). 210 patients were included in Russia, and 202 
completed the study (103M/99F): 102 patients in the spiramycin ( S )  
group and 100 patients in the roxithromycin (R) group. In a study 
using ELISA to detect IgM, IgG and IgA antibodies to Chlamydia spp., 
and IgM and 1gG antibodies to Mycoplasma pneumoniae, sera from 72 
CAP patients were evaluated. 
Results: Chlamydia serology (IgM and/or IgG) was positive in 
42/72 CAP patients. Mycoplama serology (1gM and/or I&) was posi- 
tive in 22/72 CAP patients. 'Success' (clinical improvement and clin- 
ical cure) was shown by 99/102 (S) versus 96/100 (R). 
Conclusions: The results of this local study demonstrate non- 
inferiority of spiramycin to roxithromycin in the treatment of CAP 
and AECB. Thus, spiramycin can be administered in the treatment 
of CAP and AWB. 
Efficacy and tolerance of amoxycillin (AMOX) 1 
g b.i.d. versus amoxycillin 500 mg t.i.d. in the 
treatment of acute exacerbations of chronic 
bronchitis (AECB) 
N. Vetter', A. GeorgopouIos*, M. Borek3, the Bronchitis Study 
Group. 'Pulmological Center, Vienna, 'Department .f Chemotherapy, 
University .f Vienna, 'Medizinische Abteilung, Biochemie CmbH, 
Kundl, Austria 
395 patients with clinical diagnosis of AECB were included in a 
randomized, double-blind, double-dummy, multicenter study, and 
were treated for 10 days either with AMOX 1 g b.i.d. or AMOX 500 
mg t.i.d. Assessments were made during therapy (days 3-5), after end 
of therapy (EOT, days 12-15) and at follow-up (FU, days 28-35). 
Sputum samples were collected at inclusion for pathogen identifica- 
tion. Clinical response was defined as success (cure/improvement) or 
failure at EOT. 
375 patients were clinically evaluable in the ITT population, 337 
in the per-protocol (PP) subgroup. All 395 patients were evaluated 
for safety analysis. 265 of 375 clinically evaluable patients (71%) were 
bacteriologically evaluable at baseline assessment. Both regimens 
were well tolerated; the most frequently reported drug-related 
adverse events in each group were gastrointestinal symptoms (b id .  
11.1% versus t i d .  11.6%), mostly diarrhea and nausea, which were 
mainly of mild or moderate severity 
Both dosage regimens were clinically equivalent in AECB. Clinical 
success at EOT 
A b s t r a c t s  2 7 7  
1 g bid 500 mg fid bid-tid (95 ./. C.I.) 
I l T  162/187(867%) 161/188(85.6%) I I % (-6.0%,7.9%) 
PP 1561175(891 %) 150/162(92.6%) - 3 . 5 %  ( - 9 . 6 % 2 7 % )  
Clinical recurrence rate at FU 
ITT 2211 43 (I 5.4 %) 22/147 ( I  5%) 0.4 % (- 8.7 76% 7 8 %) 
PP 18/134(13.4%) 18/131 (13 7%) -0.3 % (- 79%. 8.6%) 
v) Community-acquired sinusitis: pathogens and 
their antimicrobial susceptibility 
I .  Otyagin, E. Kanianin, E. Voronov, S. Chubarova, V Shevkov, L. 
Nekrasova. State Medical Academy, Smolensk, Russia 
Objectives: To investigate the spectrum of microbial agents in 
patients with acute paranasal sinusitis. 
Methods: 80 patients 16-69 years old were included in the study. 
Puncture of the maxillary sinus was performed in all patients before 
treatment. Aspirate and/or sinus lavage fluid were placed into Port- 
A-Cul transport medium (BBL, USA). 
Results: Pathogens were isolated in 70.0% of patients. Causative 
agents were obtained in monoculture in 82.1% of patients. Gram- 
positive and Gram-negative aerobic monocultures were isolated in 
73.1% of cases, and microbe associations were observed in 17.9% 
(aerobic associations were found in 9.1%, anaerobic in 5.4%, aero- 
boanaerobic in 3.7%>). The most common causative agents of acute 
sinusitis were S. pneumoniae (48.2%), H.  injuenzae (12.5%), and non- 
spore-forming anaerobes (9.1%). Less common were the following 
pathogens: S. aureus in 3.7% of cases, M .  catarrhalis in 1.8%, and S. 
pyogenes in 1.8%. P assacckarolytica was found among anaerobic 
cultures at a level of 3.7%. Penicillin-resistant pneumococci were 
infrequent in patients (3.0%)). The niajor problem is the resistance of 
pneumococci to co-trimoxazole (39.4%). All the strains of S. pneu- 
moniae were sensitive to cefuroxime, and 91.0% to ceftibuten; 3.0% 
o f  strains were moderately resistant and 6.0% resistant to ceftibuten. 
All the strains of S. pneumoniae were sensitive to ampicillin and co- 
amoxiclav. 88.9% strains were sensitive to ampicillin, but 11 .I% 
strains were moderately sensitive. All the strains of H .  inzuenzae were 
sensitive to ceftibuten and 88.9% to cefuroxime; 11.1% ofstrains were 
moderately sensitive. The investigation of the sensitivity of H. injuen- 
zae revealed high-level (22.2%) resistance to co-trimoxazole. All the 
strains of H. influenzae woe sensitive to co-amoxiclav. All strains of S. 
aureus were sensitive to cefuroxime, co-amoxiclav and co-trimoxa- 
zole, and resistant to ceftibuten. 3 strains of S. aureus were resistant 
to penicillin and ampicillin. P Juoiescens showed resistance to all 
antibiotics investigated in this study. C. diversus was sensitive to 
cefuroxime, ceftibuten, co-amoxiclav and co-trimoxazole, but resis- 
tant to ampiciliin. 
Conclusions: The most conimon causative agents of acute niaxil- 
lary sinusitis in this study were S. pueumoniae and H. ittfluenzae. S. 
aureus, S. pyogenes and M .  catarrhalis are not important agents of acute 
sinusitis. Sensitivity to the investigated antibiotics varied significantly 
among the different species 
[m] Five days of treatment with cefuroxime axetil 
compared with 10 days of treatment with 
clarithromycin in acute sinusitis 
W. Elies. Sthdtische Kliniken, Bielefeld, Germany 
Objectives: To show therapeutic equivalence between 5 days of 
treatment with cefuroxime axetil (A) and 10 days of treatment with 
clarithromycin (B) in patients with acute sinusitis. 
Methods: 301 patients with acute sinusitis were recruited In 28 
German study centers (ENT specialists) during winter 1997/98. The 
patients were clinically examined, and microbiological evaluation of 
the purulent nasal discharge was performed; X-ray or ultrasound 
examination confirmed the diagnosis. The patients were randomly 
assigned (1:l) to receive either cefuroxime axetil (250 mg b.i.d.) or 
clarithromycin (500 nig b id . ) .  Three visits were planned: a t  admis- 
sion on day 0, on day 3 (optional) and for final exainination (day 5 
in group A, day 10 in group B). A follow-up vitit was scheduled for 
treatment A on days 11-1 3. 
Results: 96.9% (66.2% cure, 29.7% improvement) of the cefurox- 
ime axetil group on day 5 and 95.8% (69.9% cure, 25.9% improve- 
ment) of the clarithromycin group on day 10 were considered as 
treatment successes. N o  relapse was seen in the cefuroxinie axetil 
group between day 5 and day 10. The bacteriologic results for both 
compounds were similar for all primary causative pathogens except 
for Haentophilus infuenzue (4 failures in the clarithroiiiycin group, 1 
failure in the cefuroxime axetil group). 25 patients in group A and 
30 patients in group €3 experienced adverse events. Primary bacteri- 
ologic examinations showed 40% Staphylomcus a u r a s .  
Conclusions: It can be concluded from this study that 5 days of 
therapy with cefuroxime axetil is therapeutically equivalent to 10 days 
of treatment with clarithromycin in the treatment of acute sinusitis. 
[E] Azithromycin in acute sinusitis in adults 
0. Karpov, A. Zaitsev. Department of Pharmafoepidemiolo~~ Institute 
.f P!iarmacolo,qy, St Petersbuq, Russian Federation 
Azithroniycin is an azalide antibiotic with a broad spectrum of activ- 
ity It has a prolonged biological half-life and elimination from nasal 
sinuses is slow. 
From a group of 100 adults with a confirnied diagnosis of acute 
sinusitis, 50 were randomly chosen to receive azithroniycin 
(Surnamed) 500 mg once daily for 3 days (group I), and 50 co-aniox- 
iclav (Klavocin) 625 mg t.i.d. for 10 day\ (group 11). Clinical cxani- 
inatioii was performed at baseline and 72 h, and 10-12 and 26-30 
days after initiation of treatment. Each sign and symptom was scored 
and clinical findings were expressed by total clinical score (TCS). 
TCS was significantly lower in group I 72 h after the beginning of 
treatiiient and at 10-12 days. At days 19-12 of therapy, 41 (82'X) 
patients in group I and only 26 (52%)) in group I1 were free of tynip- 
tonis. In the follow-up assessment, satisfactory clinical response was 
indicated in both groups, but the positive dynamics of symptoms 
were faster in group I. Out  of 100 patients who were included in the 
study, 85 displayed positive culture of sinus aspirate. Bacteriologic 
eradication was achieved in a majority of cases in both groups. The 
cost oftreatment in group 1 was, on average, 30%) lower than in group 
11. Within a 6-month period, 16.7% of group I1 experienced a 
relapse. 
The treatment of acute sinusitis by 3 days of azithroniycin is as 
effective as 10 days of co-amoxiclav, but azithroniycin provides a 
faster clinical effect, does not lead to relapse, and has better phar- 
maco-economic outcomes, which is important for conipliance. 
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Short-course treatment of acute sinusitis with 
moxifloxacin versus cefuroxime-axetil 
R. Sieged, D. Bagger-Sjoback'. P. Gehanno', I? Nikolaidis4, the 
Moxifloxacin Sinusitis Study Group. 'Medizinische Universith't, 
Liibeck, Germany; 'Karolinska Hospital, Stockholm, Sweden; 'Bichat 
Claude-Bernard Hospital, Paris, Frame; 4 A H E P A  University, 
nessnfoniki ,  Greece 
Objectives: To compare the safety and efficacy of moxifloxacin 
(MFX), 400 mg once daily for 7 days, with cefuroxime-axetil (CEF), 
250 mg twice daily for 10 days, in the treatment of acute bacterial 
sinusitis. 
Methods: A total of 498 patients with acute bacterial sinusitis that 
was either bacteriologically documented or clinically suspected on 
the basis of radiologic sinus X-ray and two or more clinical symp- 
toms of acute sinusitis were enrolled in the study A total of 436 
patients (87.5%) were valid for efficacy (PP) analysis, 21 1 MFX and 
225 CEF; 224 patients (51.2%) were microbiologically valid, 109 
MFX and 115 CEF. 
Results: Clinical success rates at end of therapy (EOT) were: 
MFX 96.7%. CEF 90.7% (95% C; I.%%, 10.6%). Bacterial eradica- 
tion: 
The incidence of adverse drug reactions was 31.4% with MFX and 
23.1% with CEF, and discontinuations were similar in both groups. 
Conclusions: The clinical and bacteriologic response at EOT in 
this trial demonstrates that MFX is superior to CEE Both drugs were 
well tolerated. 
lp7221 Incidence of pathogenic microorganisms in 
otics exudates from an extra-hospital 
population 
M.A. Orellana, M. Aramendi, G. Galera, C. Moyano, M.A. 
Amerigo. Department of Microbiolqy, Ambulatorio 'Hermanos Miralles', 
Madrid, Spain 
Objectives: To study retrospectively the microorganisms isolated 
&om otics exudates in the outpatient population living in the south- 
western area of Madrid (Spain). 
Materials and methods: 1255 otics exudates were studied from 
patients aged from 1 month to 91 years, during June 1994 to 
September 1998.The samples were cultured on 5% sheep blood agar, 
chocolate blood agar, broth thioglycollate (subcultured in blood agar 
and chocolate blood agar after 18-24 h), and chloramphenicol- 
gentamicin Sabouraud agar. Bacteria and yeast were identified on the 
microScan System (DADE) and filamentous fungi by microscopic 
exatnination. 
Results: The incidence of positive results was 63.9% (802). Two 
or more microorganisms (10.8%) were isolated from the same samples 
(87). The most frequently isolated microorganisms were: S. aureus 
( 2 8 3 4 ,  I? aerufinosa (23.2%), Candida sp. (16.6%), Aspergillus 
(10.3%), P mirabilis (9.2%), Penicillium (3.0%), E~-rteroburter sp. (1.8%), 
H .  influenzae (l.8%), E. coli (1.5%), Serratia marcescens (1.4%), and 
others (2.7%)). The proportions of microorganisms isolated every year 
were: 19.12% in 1994, 14.72%) in 1995, 25.66% In 1996, 21.37% in 
1997,and 14.72% in 1998. The most frequent microorganism distri- 
bution according to the season was: I? aeruginosa in November; I? 
mirabilis in October, November and February; Candida sp. in 
September; and filamentous fungi in September. 
Conclusions: An elevated proportion of positive cultures was 
found. The most frequently isolated microorganisms were: S. aureus, 
l? aeruginosa, Candida sp., filamentous fungi and l? mirabilis. A high 
proportion of microbial association (2 or more cultures) has been 
found. There was a relationship between the isolated microorganism 
and the season. 
Fungal infections I 
I P723 I Candida parapsilosis fungemia in cancer 
patients-incidence, risk factors and outcome 
in a single cancer institution within the last 10 
years 
V. Krcmery Jr', J. Trup12, I .  Krupoval, A. Roidova'. 'School of 
Public Health, University of Znava, Znava, 'National Cancer Institute, 
Bratislava, Slovak Republic 
All cases of fungemia caused by C. parapsilosis in a single cancer insti- 
tute within 10 years, in order to compare risk factors and the 
outcome with C. albicans and other non-albicans Candida spp., are 
analyzed. Before 1990 (1988-89) no C. parapsilosis fungemias were 
observed at all. During 1990-96, the proportion of C. parapsilosis 
among fungemias increased from &7.1% in 1990-93 to 14.2-1596 
in 1996-97.This organism therefore represents 25% of non-albicans 
Candida spp. fungemias and 7.9% of all fungemias and is the third 
commonest pathogen after C. albicans (50.5%) and C. krusei (9.9%). 
Two of eight (25%) C. parapsilosis fungemias were breakthroughs; one 
appeared during prophylaxis with ketoconazole, and one with 
fluconazole. According to the univariate analysis, the infected vascu- 
lar catheters were, surprisingly, not the major risk factor, and of 7 
patients of 8 (87.8%) who had the vascular catheter inserted, the 
catheter was documented as the source of fungemia only in 2 cases. 
The commonest determined risk factors were similar to those occur- 
ring with other fungemias-such as previous antimicrobial therapy 
(62.5%). neutropenia (50%) and prior prophylaxis with azoles. 
Comparison of 8 C. parapsiloris fungemias with 51 C. albicans 
fungemias occurring during the same period and in the same insti- 
tute, and with 32 non-albicans Candida spp. in the same period and 
institute and with an identical antifungal policy, showed that there 
were no significant differences in risk factors. Both attributable and 
crude mortality were also similar to C. albicans and non-albicans 
Candida spp. fungemias. 
Candida fungemia in neonates treated with 
fluconazole: report of 40 cases, including 8 
meningitis 
M. Huttovi, V. Krcmery Jr. J. Filka, K. Kralinsky, I .  Hartmanova, J. 
Kurak, J. Fric. Pediatric Clinic, Postgraduate Medical School, Brutislava; 
University of Znava, Znava, Slovak Republic 
Objectives: To assess the efficacy and safety of fluconazole in 
neonates with Candida fungemia. 
Methods: Multicenter prospective protocol of all fungemias 
appearing between 1 January 1993 and 31 December 1997 in four 
major university hospitals. 
Results: Forty neonates, 28 of them with very low birth weight 
(1500 g) (30.5 median gestation week), with documented Candida 
albicans fungemia were treated with intravenous fluconazole at a daily 
